Ryan Preblick is the Chief Financial Officer of Indivior Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing innovative treatments for opioid use disorder and serious mental health conditions. Appointed in March 2022, Preblick leads the company's global finance organization, overseeing financial planning and analysis, treasury, tax, investor relations, and capital allocation strategies. His leadership has been instrumental in driving financial discipline, optimizing the capital structure, and supporting Indivior's mission to transform addiction treatment amid evolving regulatory and market dynamics. With over two decades of experience in the pharmaceutical and healthcare sectors, Preblick brings a proven track record of navigating complex financial challenges. Prior to Indivior, he served as CFO at Mallinckrodt Pharmaceuticals from 2019 to 2022, where he spearheaded a comprehensive financial restructuring that reduced debt by billions and stabilized operations during a period of litigation and market pressures. Earlier, he was Senior Vice President of Finance and Interim CFO at Purdue Pharma, managing financial operations through significant transformations, and held progressive finance roles at Reckitt Benckiser plc, honing his expertise in multinational corporate finance and mergers and acquisitions. Preblick's achievements include fostering sustainable growth and resilience in high-stakes environments, earning recognition for his strategic acumen in debt management and operational efficiency. At Indivior, he continues to advance initiatives that enhance shareholder value, support R&D investments in novel therapies like SUBLOCADE and OPVEE, and position the company for long-term success in addressing global public health challenges.